Phase II Study of Abiraterone Acetate Plus Prednisone in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Demonstrating Radiographic Flare Discordant With Serologic Measures of Response

PURPOSE: Abiraterone is an oral inhibitor of CYP17, essential for androgen biosynthesis. This multicenter study assessed its efficacy in patients with CRPC without prior exposure to chemotherapy or CYP17 targeted therapy, and assessed the frequency of interpretation of bone scans discordant with PSA...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Ryan, Charles J., Shah, Shreya, Efstathiou, Eleni, Smith, Matthew R., Taplin, Mary-Ellen, Bubley, Glenn J., Logothetis, Christopher J., Kheoh, Thian, Kilian, Christine, Haqq, Chris, Molina, Arturo, Small, Eric J.
Formato: Artigo
Idioma:Inglês
Publicado: 2011
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3657705/
https://ncbi.nlm.nih.gov/pubmed/21632851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-0815
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares